[18F]MK-6240

DRUG4 trials

Sponsors

UZ Leuven, F. Hoffmann-La Roche AG, Genentech, Inc., LuMind IDSC Foundation

Conditions

Alzheimer Disease (AD)Alzheimer disease in a preclinical and prodromal stageCognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer’s Disease (AD)Down Syndrome

Phase 1

Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease

CompletedNCT04566003

Genentech, Inc.Alzheimer Disease (AD)

Start: 2020-10-26End: 2023-06-27Updated: 2023-07-12

Phase 3

Cognitive brain circuits and the spread of tau in vivo in humans.

RecruitingCTIS2024-511613-38-01

UZ LeuvenAlzheimer disease in a preclinical and prodromal stage

Start: 2018-05-18Target: 160Updated: 2024-08-27

LIFE-DSR-Biomarker Sub-study of Biomarkers in Down Syndrome Related Alzheimer's Disease (DS-AD)

TerminatedNCT06860373

LuMind IDSC FoundationDown Syndrome

Start: 2023-06-27End: 2024-04-17Updated: 2025-03-06

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer’s Disease

Not yet recruitingCTIS2025-524314-29-00

F. Hoffmann-La Roche AGCognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer’s Disease (AD)

Target: 19Updated: 2026-09-29